18F-HX4 hypoxia imaging with PET/CT in head and neck cancer
Authors:
- Zhengwei ZhangZZZhengwei Zhang
- Hartmuth C. KolbHKHartmuth C. Kolb
- Joseph C. WalshJWJoseph C. Walsh
- James ZhangJZJames Zhang
- Yihui GuanYGYihui Guan
- 1 October 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 33 (10) , 1096-1102
Abstract
Hypoxia is an important negative prognostic factor for radiation treatment of head and neck (H&N) cancer. The focus of this study was to evaluate the feasibility of 18F-HX4 (3-[18F]fluoro-2-(4-((2-nitro-1Himidazol- 1-yl)methyl)-1H-1,2,3,-triazol-1-yl)-propan-1-ol) on hypoxia imaging compared with 18F-fluoromisonidazole (18F-FMISO) mainly in human H&N cancer. 18F-HX4 precursor, standards, and methods were provided by Siemens Molecular Imaging Inc. 18F-HX4 was prepared in an automated module. Twelve patients with H&N cancer were recruited into this study. Each patient underwent 18F-HX4 PET/CT imaging, followed by 18F-FMISO and 18F-fluorodeoxyglucose (18F-FDG) PET/CT on separate days. 18F-HX4 and 18F-FMISO images of the H&N areas were acquired 1.5 and 2 h after injection, respectively. Standard uptake values and tumor-to-muscle (T/M) ratios were calculated. Immunohistochemical analysis of the hypoxia-associated marker CA-IX was carried out to investigate the relationship with PET uptake. 18F-HX4 and 18F-FMISO in the patients gave similar hot spots well within the 18F-FDG uptake region. At 1.5 h postinjection 18F-HX4 yielded a T/M similar to that of 18F-FMISO at 2 h postinjection (1.94±1.03 vs. 1.85±1.01; P> 0.05). A total of 12 lesions were identified. Among them, eight lesions were positive and two lesions were negative on both 18F-HX4 and 18F-FMISO images; one of the other two lesions was positive only on 18F-HX4, whereas the other one was positive only on 18F-FMISO. The CA-IX expression result correlated with the hypoxia imaging but not with 18F-FDG imaging. 18F-HX4 is a safe and feasible agent in hypoxia imaging of H&N cancer patients. We could assume that 18F-HX4 may have higher sensitivity and specificity, faster clearance, and shorter injection–acquisition time compared with traditional 18F-FMISO. Additional evaluations need to be carried out to validate the assumption. Further development of 18F-HX4 for eventual targeting of antihypoxia therapies is warranted.Keywords
This publication has 21 references indexed in Scilit:
- Preclinical evaluation and validation of [ 18 F]HX4, a promising hypoxia marker for PET imagingProceedings of the National Academy of Sciences, 2011
- PET imaging of hypoxia using [18F]HX4: a phase I trialEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Role of hypoxia in the hallmarks of human cancerJournal of Cellular Biochemistry, 2009
- 18F-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck CancerJournal of Nuclear Medicine, 2008
- Molecular Imaging of HypoxiaJournal of Nuclear Medicine, 2008
- Hypoxia Positron Emission Tomography Imaging With 18F-FluoromisonidazoleSeminars in Nuclear Medicine, 2007
- A new synthesis of the labeling precursor for [18F]-fluoromisonidazoleJournal of Labelled Compounds and Radiopharmaceuticals, 2005
- Nitroimidazoles and imaging hypoxiaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- The Concentration of Oxygen Dissolved in Tissues at the Time of Irradiation as a Factor in RadiotherapyBritish Journal of Radiology, 1953
- A Factor of Importance in the Radio Sensitivity of TumoursBritish Journal of Radiology, 1936